Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used.
Nov 2010 - Cancer Immunol. Immunother.:1432-0851 [PMID:21069321]
[Lesterhuis WJ] [Schreibelt G] [Scharenborg NM] [Brouwer HM] [Gerritsen MJ] [Croockewit S] [Coulie PG] [Torensma R] [Adema GJ] [Figdor CG] [de Vries IJ] [Punt CJ]